Long-acting reversible contraceptives - Implant vs. Intrauterine Device; Why go for either?
نویسندگان
چکیده
Objective: To compare the clinical performance and side effects of Implant (jadelle) intrauterine contraceptive device (Cu-T). Study Design: Prospective Analytic study. Setting: Department Obstetrics & Gynaecology, PNS Shifa Hospital, Bahria University Health Sciences, Karachi. Period: 1st January 2021 to 31st December 2021. Material Methods: A total 162 married females childbearing age participated in our study, n=81 each group. Group consisted those who had subdermal implant jadelle inserted B included ladies were using devices (IUDs) for contraception. Patient with pre-existing medical disrorders levonorgestrel Intrauterine system (Mirena) excluded. They interviewed a structured questionnaire at 6-months post insertion. The outcome success/ failure rate effects. Data was analysed SPSS 22. Results: women part this Most, 30(37.03%) between 26-30 years (Implant) vs. 36 (44.4%) devices. 56 (61.7%) 68 (83.9%) regular menstruation prior use LARC; p-value 0.05 which is statistically significant. 45 (55.5%) 33 (40.7%) least secondary level education. Among two study groups, 12(14.8) 24 (29.6%) reported mild increase menstrual bleeding, 0. 000. Other noticed headache, nausea, weight gain. Conclusion: Progesterone only showed same efficacy as Copper T IUD (intrauterine devices) significantly fewer
منابع مشابه
Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant.
The provision of effective contraception is fundamental to the practice of women's health care. The most effective methods of reversible contraception are the so-called long-acting reversible contraceptives, intrauterine devices and implants. These methods have multiple advantages over other reversible methods. Most importantly, once in place, they do not require maintenance and their duration ...
متن کاملDevelopment of clinical pathways for long-acting reversible contraceptives (LARCs).
©FSRH J Fam Plann Reprod Health Care 2008: 34(2) Why was the change needed? Long-acting reversible contraceptives (LARCs) are underused and many health professionals do not feel confident about how best to provide them. In 2003, Gloucestershire Sexual Health Services were successful in bidding for a programme for the National Primary Care Contracting Collaborative. This was to improve the provi...
متن کاملGuidelines for the use of long-acting reversible contraceptives.
Volume 85, Number 4 www.aafp.org/afp American Family Physician 403 The use of long-acting reversible contraceptives (LARCs) has increased from 1.3 to 5.5 percent over the past decade. There are three LARCs available in the United States: the etonogestrel single-rod implant and two types of intrauterine devices (IUDs; copper T380A and levonorgestrel intrauterine system [Mirena]). Rates of uninte...
متن کاملReducing barriers to the use of the intrauterine contraceptive device as a long acting reversible contraceptive.
The intrauterine device (IUD) is the oldest long acting reversible contraceptive (LARC) method. There remain widespread barriers to its general acceptance, although some have been overcome, others remain. These stem from a lack of understanding of uterine anatomy and physiology. Uterine measuring techniques did not become popular, probably because of the extra effort required prior to IUD inser...
متن کاملWhy are US women not using long-acting contraceptives?
CONTEXT Given the level of unintended pregnancy in the United States, it is somewhat surprising that hormonal implants and injectables-methods that are long-acting, reversible, highly effective and convenient--have not attained the popularity enjoyed by other medical methods. Knowing the reasons why women have so far spurned these methods might lead to the design and implementation of intervent...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The professional medical journal
سال: 2023
ISSN: ['1024-8919', '2071-7733']
DOI: https://doi.org/10.29309/tpmj/2023.30.01.7304